Evidence map›Paper›PMID 22728005›Full record

Trial reportThe American journal of cardiology2012

Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Ramin S Hastings, Judith S Hochman, Vladimir Dzavik, Gervasio A Lamas, Sandra A Forman, Francois Schiele, Lampros K Michalis, Dimitris Nikas, Joanna Jaroch, Harmony R Reynolds

Registry-linked trialAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00004562 (Occluded Artery Trial), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00004562 phase3completednot on this map

Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI

TypeinterventionalSponsorNYU Langone HealthRan1999 to 2011Enrolled2,201ConditionsCardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, CongestiveArmsBeta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Ramin S HastingsCardiovascular Clinical Research Center, Division of Cardiology, New York University School of Medicine, New York, New York, USA.
Judith S Hochman
Vladimir Dzavik
Gervasio A Lamas
Sandra A Forman
Francois Schiele
Lampros K Michalis
Dimitris Nikas
Joanna Jaroch
Harmony R Reynolds
New York University · USUniversity of Ioannina · GRCentre Hospitalier Universitaire de Besançon · FRClinical Trials and Surveys Corporation · USMount Sinai Medical Center · USUniversity Health Network · CAWroclaw Medical University · PL

Funding

Occluded Artery Trial: Long Term Follow-UpU01HL062509 · NHLBI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI HOCHMAN, JUDITH S · 1999 to 2010
$11.1M
Occluded Artery Trial: Long-Term Follow up-Data Coordinating CenterU01HL062511 · NHLBI · MARYLAND MEDICAL RESEARCH INSTITUTE, INC · PI FORMAN, SANDRA · 1999 to 2010
$5.2M
NHLBI NIH HHS U01 HL062509NHLBI NIH HHS U01 HL062511
6 · The paper itself

Abstract

Renal dysfunction is an independent predictor of cardiovascular events and a negative prognostic indicator after myocardial infarction (MI). Randomized data comparing percutaneous coronary intervention to medical therapy in patients with MI with renal insufficiency are needed. The Occluded Artery Trial (OAT) compared optimal medical therapy alone to percutaneous coronary intervention with optimal medical therapy in 2,201 high-risk patients with occluded infarct arteries >24 hours after MI with serum creatinine levels ≤2.5 mg/dl. The primary end point was a composite of death, MI, and class IV heart failure (HF). Analyses were carried out using estimated glomerular filtration rate (eGFR) as a continuous variable and by eGFR categories. Long-term follow-up data (maximum 9 years) were used for this analysis. Lower eGFR was associated with development of the primary outcome (6-year life-table rates of 16.9% for eGFR >90 ml/min/1.73 m(2), 19.2% for eGFR 60 to 89 ml/min/1.73 m(2), and 34.9% for eGFR <60 ml/min/1.73 m(2); p <0.0001), death, and class IV HF, with no difference in rates of reinfarction. On multivariate analysis, eGFR was an independent predictor of death and HF. There was no effect of treatment assignment on the primary end point regardless of eGFR, and there was no significant interaction between eGFR and treatment assignment on any outcome. In conclusion, lower eGFR at enrollment was independently associated with death and HF in OAT participants. Despite this increased risk, the lack of benefit from percutaneous coronary intervention in the overall trial was also seen in patients with renal dysfunction and persistent occlusion of the infarct artery in the subacute phase after MI.

Indexed as

AgedCoronary AngiographyCoronary StenosisFemaleFollow-Up StudiesGlomerular Filtration RateHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPrognosisRenal InsufficiencyRetrospective StudiesRisk FactorsSeverity of Illness Index

Identifiers

PMID22728005
PMCPMC3439588
OpenAlexW2081615631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.